General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

Opinion
Video

TAS-102 combination with bevacizumab are highlighted in the 3L setting for colorectal cancer.

Related Videos
Video 6 "PRKAR1A-RET Fusion in Pancreatic Cancer: Unlocking New Therapeutic Frontiers"
Video 5 - "Efficacy and Safety of Tumor Agnostic Therapies"
Video 10 - "Monitoring and AE Management Strategies with Fruquintinib in CRC"
Video 9 - "FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC"
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma
Video 4 - "Challenges in Adopting Targeted Therapies for BRAF Alterations"
Video 3 - "BRAF V600E Mutant Ganglioglioma"
Video 10 - "SELECT Trial & DECISION Trial Outcomes and Lessons Learned"
Related Content